Member Info for vares

Https://clinicaltrials.gov/study/NCT05428969?intr=Bexmarilimab&rank=4

## A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB)

[ClinicalTrials.gov](http://ClinicalTrials.gov) ID NCT05428969

Sponsor Faron Pharmaceuticals Ltd

Information provided by Faron Pharmaceuticals Ltd (Responsible Party)

Last Update Posted 2024-08-27

Faron Pharmaceuticals

Notice of Half-Year Financial Results

Company Announcement, 20 August 2024

TURKU, Finland - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, will report its unaudited half-year financial results for the six months ended June 30, 2024, on Tuesday, 27 August 2024.

A live hybrid briefing and Q&A session for investors, analysts and media will be hosted by Dr. Juho Jalkanen, Chief Executive Officer, and Yrjö Wichmann, Chief Financial Officer, at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST) on Wednesday, 28 August 2024.

Webcast registration link: https://faron.videosync.fi/q2-2024

Live participation

In addition to the webcast, there are a number of spaces available to attend the briefing in-person at Studio Eliel in Sanomatalo at Töölönlahdenkatu 2, Helsinki. To register, please contact

investor.relations@faron.com no later than 10:00 a.m. EEST on Monday, 26 August 2024. Please note that places are limited, and you will receive a separate email confirmation.

The half-year report, presentation, and a replay of the webcast will be available on the Company's website at www.faron.com/investors.

Https://otp.tools.investis.com/clients/uk/faron2/rns/regulatory-story.aspx?cid=2223&newsid=1853682

Helsinki just now +20%

Https://www.faron.com/sites/faron-corp/files/Faron%20Corporate%20Presentation%20non-conf%2006%202024.pdf

It just that hopeful article in the Finnish paper.

Volume now 101000, 12,7%

Excerpt from Juho Jalkanen's interview in today's newspaper:

"When phase 2 is taken care of and the FDA's feedback resolves the needs for further investments, we can bring the partnership to the finish line," says Jalkanen.

"The partner will probably come during this year. Industry practice is that phase 2 data is usually partnered with. It may be that the partner's bidding will stretch the process, but the completion of the studies and the final investments will be left to the big pharmaceutical company," says Jalkanen.